This clinical trial focuses on treating people with obesity and pre-diabetes. The study will test two medications: semaglutide, which is an anti-diabetic and anti-obesity medication, and pramlintide acetate, which helps stabilize blood glucose levels. The study aims to examine how these medications work together to affect metabolism, body composition, and feelings of hunger and fullness in people with these conditions.
During the study, participants will receive semaglutide for 25 weeks, followed by one week where pramlintide is added to the treatment. Throughout the study, participants will undergo various tests to measure how their body responds to food and how quickly their stomach processes it. One of these tests involves taking paracetamol, a common pain reliever, to measure how fast food moves through the stomach.
The researchers will measure changes in how much food participants eat during test meals and track weight loss throughout the study. They will also monitor how participants feel about their appetite and fullness levels. The study will last approximately 26 weeks, during which the medications will be given through subcutaneous injection under the skin.
Denmark 
